eBlu Solutions to Sponsor and Exhibit at 2024 NORM Conference

eBlu Solutions experts will be onsite to showcase complete benefit investigation and prior authorization support for rheumatology practices

LOUISVILLE, KY, August 12, 2024– eBlu Solutions, a SaaS+ specialty healthcare solution provider in the benefit verification and prior authorization space, is proud to announce its sponsorship and exhibition at the 2024 NORM Conference, where experts will be showcasing comprehensive benefit investigation and prior authorization support tailored specifically for rheumatology practices. Taking place from September 12-14 at the Gaylord Texan Resort and Convention Center in Grapevine, Texas, this annual event brings together practice managers, rheumatologists, and industry colleagues to explore educational opportunities, discuss industry trends, and strategize on how to thrive in the marketplace.

Kim Farley, Founder & Chief Operations Officer at eBlu Solutions, expressed enthusiasm for the ninth consecutive year of sponsoring the NORM Conference, emphasizing the company’s commitment to supporting rheumatology practices nationwide. “The team looks forward to engaging with current eBlu practices, as well as reaching out to potential partners in Texas, to demonstrate how eBlu can expedite patient access to treatment – all at no cost to them

Since 2012, eBlu Solutions has been dedicated to providing specialty healthcare practices, with a cloud-based software solution for verifying medical benefits and obtaining prior authorizations. Their focus is on streamlining processes to ensure that practices can efficiently support patients in need of high-cost infusion and injection treatments.

To learn more about eBlu Solutions and their innovative healthcare solutions, visit www.eblusolutions.com.

About eBlu Solutions

eBlu Solutions provides a secure single-portal software platform for electronic prior authorization and benefits verification in the infusion-based specialty medication space. eBlu Solutions aims to streamline the fragmented nature of the approval process for specialty medication treatments, and currently supports a variety of specialties including rheumatology, neurology, gastroenterology, and allergy & asthma.